Lanreotide

ATC H01CB03 · 9 markets · 69 records

Lanreotide 9 markets · 69 records Forms

GB 19 records · 6 strengths

US 13 records · 3 strengths

AU 8 records · 4 strengths

  • 120 mg/0.5 mLinjectionMytolacSOMATULINE AUTOGEL also in GB·US
  • 90 mg/0.5 mLinjectionMytolacSOMATULINE AUTOGEL also in GB
  • 60 mg/0.5 mLinjectionMytolacSOMATULINE AUTOGEL also in GB

Records without a stated strength · 1 Mytolac、SOMATULINE AUTOGEL

CA 6 records · 3 strengths

  • 120 mgliquid · extended-releaseMytolacSOMATULINE AUTOGEL
  • 90 mgliquid · extended-releaseMytolacSOMATULINE AUTOGEL
  • 60 mgliquid · extended-releaseMytolacSOMATULINE AUTOGEL

ES 6 records · 3 strengths

CN 3 records · 3 strengths

  • 120 mginjection · extended-releaseManufacturer: IPSEN PHARMA ×2 also in TW
  • 90 mginjection · extended-releaseManufacturer: IPSEN PHARMA ×2 also in TW
  • 40 mginjection索马杜林醋酸兰瑞肽

TW 3 records · 3 strengths

HK 3 records · 1 strengths

    Records without a stated strength · 1 SOMATULINE AUTOGEL INJ 120MG (PREFILLED-SYRINGE)

    The same ingredient can carry completely different brand names in different countries, and the same name can point to a different ingredient. Listed by country — not interchangeable.

    Discontinued, withdrawn or unverified-status products are hidden by default; Hong Kong and Australia records are shown as exceptions.

    A side-by-side table is offered only when this ingredient has records in many markets; otherwise this list is the whole picture.